Table 4.
In-hospital and discharge characteristics of the DOSE trial population stratified by relative agreement between fluid and weight loss
| Characteristic | Fluid and weight loss within ± 50% (N=122) | Fluid ≥50% more than weight loss (N=84) | Weight ≥50% more than fluid loss (N=48) | p-value |
|---|---|---|---|---|
| In hospital treatment | ||||
| Inotrope | 11.5% | 11.9% | 12.5% | 0.982 |
| Vasodilator | 8.2% | 3.6% | 8.3% | 0.375 |
| Thiazide diuretic | 22.9% | 16.3% | 11.6% | 0.229 |
| Total study drug loop diuretic (mg) † | 509 (310–829) | 483 (288–735) | 436 (226–733) | 0.448 |
| Total open label loop diuretic (mg)† | 0 (0–53) | 0 (0–75) | 0 (0–125) | 0.742 |
| Total loop diuretic (mg)† | 598 (383–892) | 570 (325–870) | 536 (340–766) | 0.571 |
| In hospital findings/outcomes | ||||
| Fluid intake (ml)† | 4113 ± 1319 | 4270 ± 1430 | 4343 ± 1809 | 0.740 |
| Fluid output (ml)† | 9134 ± 3409 | 8474 ± 2772 | 5967 ± 2116 | 0.000* |
| Ratio of intake to output† | 0.5 ± 0.2 | 0.6 ± 0.3 | 0.7 ± 0.2 | 0.000* |
| Net fluid output (ml)† | 5021 ± 3221 | 4204 ± 2528 | 1624 ± 1503 | 0.000* |
| Weight loss (kg)† | 4.9 ± 3.0 | 1.3 ± 1.5 | 3.1 ± 7.3 | 0.000* |
| Congestion free at 24 hours | 3.3% | 1.2% | 2.1% | 0.616 |
| Congestion free at 48 hours | 7.6% | 6.0% | 6.4% | 0.905 |
| Congestion free at 72 hours | 13.0% | 6.4% | 14.6% | 0.266 |
| Patients’ global assessment of symptoms† | 4408 ± 1394 | 4166 ± 1510 | 4065 ± 1260 | 0.255 |
| Treatment failure† | 35.2% | 40.5% | 41.7% | 0.644 |
| Worsening or persistent HF | 23.8% | 29.8% | 25.0% | 0.619 |
| Length of stay (days) | 5 (3–9) | 6 (4–9) | 6 (3–10) | 0.108 |
| Change in laboratory parameters from randomization to 72 hours | ||||
| NTpro-BNP (pg/ml) | −674 (−2580 to 27) | −957 (−2836 to 264) | −994 (−2581 to −216) | 0.847 |
| Creatinine (mg/dl) | 0.4 ± 0.3 | 0.0 ± 0.3 | 0.1 ± 0.3 | 0.166 |
| Increase in creatinine ≥ 0.3 mg/dl | 12.3% | 17.9% | 27.1% | 0.066 |
| Cystatin-C (mg/L) | 0.1 ± 0.3 | 0.1 ± 0.4 | 0.2 ± 0.4 | 0.678 |
| eGFR (ml/min/1.73m2) | −2.2 ± 11.3 | −1.1 ± 10.6 | −3.1 ± 12.9 | 0.501 |
| Blood urea nitrogen (mg/dL) | 0.9 ± 10.1 | 3.2 ± 13.0 | 5.5 ± 9.1 | 0.022* |
| Serum sodium (mmol/L) | 0.1 ± 3.2 | 0.3 ± 3.4 | −1.0 ± 3.6 | 0.130 |
| Medications (Discharge) | ||||
| β-Blocker | 75.2% | 86.7% | 78.3% | 0.129 |
| ACE inhibitor or ARB | 59.5% | 59.0% | 60.9% | 0.979 |
| Digoxin | 32.2% | 44.6% | 30.4% | 0.134 |
| Thiazide diuretic | 14.8% | 12.3% | 16.3% | 0.814 |
| Loop diuretic dose (mg) | 160 (80–200) | 160 (80–240) | 160 (80–160) | 0.546 |
| Aldosterone antagonist | 35.5% | 37.3% | 32.7% | 0.865 |
| Discharge Physical Examination findings | ||||
| Heart rate (beats/min) | 78 ± 16 | 76.5 ± 13.0 | 77.0 ±11.5 | 0.900 |
| Systolic blood pressure (mmHg) | 109 ± 15 | 112 ± 19 | 113 ± 17 | 0.629 |
| Jugular venous distention | 15.4% | 16.0% | 29.2% | 0.305 |
| Edema | 42.6% | 39.2% | 19.6% | 0.628 |
NTpro-BNP: N terminal pro B-type natriuretic peptide, eGFR: Estimated glomerular filtration rate. ACE: Angiotensin converting enzyme, ARB: Angiotensin receptor blocker.
†
variable ascertained from randomization to 72 hours.
*
Significant p value.